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of survival functions, used Cox proportional hazard models, and
adjusted standard errors to account for survey design. RESULTS:
The duration of treatment was not different for the 3 interferons
and Copaxone, with 72% of patients continuing with the
therapy after 3 years, while 1.7% of patients on Novantrone
continued treatment after 3 years. Having SPMS increased the
risk of terminating DMA by 67% (p = 0.01) and having moder-
ate disability increased the risk by 77% (p = 0.001) compared
with less advanced disease. Older patients and those with longer
duration of MS were more likely to stay on DMA. Doctor’s
advice was the main reason for starting (47%) or stopping (20%)
DMA therapy, followed by side effects (10% and 27%, respec-
tively), and burden of drug administration (15% and 10%,
respectively). After Avonex, 37% of patients did not take any
DMA for at least 6 months, 17% switched to Copaxone and
15% to Rebif. After Betaseron, 51% stayed off DMAs while
19% switched to Copaxone. 37% of Copaxone users switched to
no DMA, and 16% switched to Avonex. CONCLUSION: The
majority of MS patients continued treatment for three years and
more. Consistent with the risk of cardiotoxicity associated with
long-term use, most patients discontinued Novantrone within
three years.
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OBJECTIVE: Generic substitution of antiepileptic drugs (AEDs)
may be problematic in patients receiving multiple generics
because variability in drug serum concentrations can induce
breakthrough seizures. To investigate clinical consequences of
generic substitution of one versus multiple generics of topiramate
(Topamax®). METHODS: Claims data of Régie de l’assurance-
maladie du Québec (RAMQ) from January 2006-October 2007
were used. Patients with epilepsy (ICD-9 345 or 780.3) treated
with topiramate (Canadian patent expired January 2006) were
selected. An open-cohort person-time design was used to classify
the observation period into mutually exclusive periods of brand,
single-generic, and multiple-generic use. One-year switching
rates of brand-to-generic and switchback-to-brand were com-
puted using Kaplan-Meier methodology. Medical resource utili-
zation (frequency per person–year) was compared among the
three periods using multivariate regressions adjusted for demo-
graphics, treatment characteristics and comorbidities. RESULTS:
A total of 948 patients were observed during 1105 person-years
(p/y) of brand use, 233 p/y of single-generic use, and 92 p/y
of multiple-generic use. Approximately 38% of brand users
switched to generic topiramate, of whom 14% switched back to
brand. Generic users received on average 1.4 generic versions,
with 23% taking two or more versions. Multiple-generic use was
associated with increased utilization of both AEDs and non-AED
drugs compared to brand (RR = 1.27, 95%CI = 1.24; 1.31) and
single-generic use (RR = 1.10, 95%CI = 1.06; 1.13) after covari-
ate adjustment. Multiple-generic use was associated with sig-
niﬁcantly higher hospitalization rate (0.48 vs. 0.83 visit/p/y,
RR = 1.65, 95%CI = 1.28; 2.13) and hospital length of stay (2.6
vs. 3.9 days/p/y, RR = 1.43, 95%CI = 1.27; 1.60), but the effect
was less pronounced in single-generic use (hospitalization:
RR = 1.08, 95%CI = 0.88; 1.34, length of stay: RR = 1.12,
95%CI = 1.03; 1.23). The risk of head injury or fracture was
5 times higher (HR = 5.43, 95%CI = 4.23; 6.97) following a
generic-to-generic switch compared to brand use. CONCLU-
SION: Multiple-generic substitution of topiramate was signiﬁ-
cantly associated with outcomes, such as hospitalizations,
fractures and injuries.
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OBJECTIVE: To examine if pharmacological treatment of
insomnia varied with patient’s gender, ethnic, or both.
METHODS: This was a cross-sectional study using data from
2004 National Ambulatory Medical Care Survey (NAMCS) by
National Center for Health Statistics. We identiﬁed visits at
which at least one frequently used insomnia prescription was
prescribed as deﬁned from the American Insomnia Association.
A series of population-based descriptive analyses were performed
to estimate the national weighted frequency of each drug.
Weighted chi-square statistics were used to compare insomnia
drugs uses by patients with different gender and ethnic charac-
teristics. To provide national estimates, all analyses incorporated
sample weights and standard errors corrections to adjust for the
complex sampling design employed by NAMCS. RESULTS: A
total of 910 million outpatient visits were estimated in the US. in
2004. A total of 24.98 million visits at least one insomnia pre-
scription was prescribed including 3.38 million visits(13.6%)
with FDA approved benzodiazepine receptor agonist; 8.5 million
visits(34.1%) with FDA approved non-benzodiazepine receptor
agonist; and 13.1 million visits (52.4%) with antipsychotic medi-
cations which is used for insomnia treatment without FDA
approved. Female received signiﬁcant more insomnia prescrip-
tion than male (16.4 mil. VS. 8.58 mil., P < 0.0001). Patients
who are Black and Hispanics received less insomnia prescription
than those who are white (P < 0.0001). CONCLUSION: The
study found a signiﬁcant gender and ethnic disparities in the use
of insomnia prescriptions especially to the use of related costly
non-benzodiazepine receptor agonist. The problems of access
barriers to health care for the minority population are still sig-
niﬁcant. The study also provided evidence that the non-FDA
approved prescription medications that were used signiﬁcantly
frequent to treat insomnia than currently approved agents. The
issue of off-label treatment for sleep has been raised concerns
about the adverse effects that develop during the insomnia treat-
ment and limit the efﬁcacy of these medications.
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OBJECTIVE: Since the early 1990s BoNT-A has been used as
prophylaxis treatment for headaches, including migraine. Evi-
dence suggests that this use is primarily in migraine patients who
are refractory to other prophylaxis treatments. This analysis aims
to evaluate the patterns of use and the characteristics of patients
treated with botulinum toxin type A (BoNT-A; BOTOX®; Aller-
gan, Inc, Irvine, CA) for migraine or headache. METHODS: A
retrospective, database claims analysis examining pharmacy and
medical claims from the Source Lx database (WoltersKluwer
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Health) was conducted. SourceLX contains linked prescription
and diagnosis claims for $35 million patients with insurance
coverage from a variety of sources. Data were screened to identify
records between December 1, 2005 and November 30, 2006 with
a medical claim for BoNT-A (UB92 or CMS1500) and an ICD-9
diagnosis for headache or migraine on the same claim.RESULTS:
In the 12-month analysis period, approximately 2.88 million
people visited a physician for headache or migraine. Only 1754
patients (0.06%) received treatmentwith BoNT-A; the vastmajor-
ity (80%) had a speciﬁc diagnosis of migraine, not a general
diagnosis of headache. BoNT A recipients were between 40–59
years of age (46%) and most were female (83.1%); BoNT-A
treatment was most often (84%) prescribed by a neurologist.
Fewer (26%) BoNT-A treated users compared to non- BoNT-A
users (52%) were using more than one medication to treat head-
ache or migraine symptoms. In BoNT-A users, the use of combi-
nation pain medication (2 of the following: opioid analgesic,
non-narcotic analgesic, topical anesthetic, NSAID or synthetic
narcotic) was signiﬁcantly reduced in the 90 days after BoNT-A
treatment (p < 0.01). CONCLUSION: BoNT-A treated users are
mostly migraine sufferers. BoNT A treated patients required less
pain medication. Further research needs to be conducted to deter-
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OBJECTIVE: To summarize clinical rates in treating neuropathic
pain of three drug classes: tricyclic antidepressants (TCAs),
serotonin-norepinephrine reuptake inhibitors (SNRIs), and anti-
convulsants (ACs). METHODS: Patients included adults diag-
nosedwith neuropathic pain experienced >3months.We accepted
double-blinded randomized clinical trials using any drug within
these classes against placebo/active comparator. Outcomes re-
ported were pain score changes on a visual analog scale (VAS),
partial response and response (30% and 50% reduction, respec-
tively), and ADR dropout rates. Two independent reviewers
searchedMedline, Embase, and Cochrane databases (inception to
2007), plus references from retrieved articles. Discrepancies were
resolved by consensus (adjudication by a third reviewer). Data
were extracted/veriﬁed similarly. Quality was similarly assessed
using Jadad’s method. Homogeneity of effects was determined
using Chi-square and I-square. Data were combined using a
random-effects model. RESULTS: From 115 articles, 84 were
excluded (45 inappropriate drugs, 20 inappropriate patients, 12
unacceptable designs, ﬁve insufﬁcient outcome data, one dupli-
cate, and one not located), leaving 28. Thirteen studies (N = 1257)
evaluated ACs (gabapentin, pregabalin), ﬁve SNRIs (N = 781),
and ten TCAs (N = 249). One evaluated both ACs and TCAs.
Quality was 81%  21% overall. Weighted mean baseline-
endpoint VAS differences were: TCAs = 1.8 (95%CI = 1.2–2.4;
13 studies, N = 249), SNRIs = 2.7 (95%CI = 2.4–3.0; 10 studies,
N = 781), and ACs = 2.4 2 were signiﬁcant and I2 were c
(95%CI = 2.0–2.8; 20 studies, N = 1257). All 63%–90%, indi-
cating heterogeneity. For partial response, we analyzed 17 study
arms (N = 1439), nine involving ACs (n = 870), four examining
SNRIs (n = 458), and four that studied TCAs (n = 111). Rates
were: SNRIs = 66.0%  2.2%, ACs = 54.5%  3.7%, and
TCAs = 49.2%  6.6%. For full response, 27 study arms were
summarized: SNRIs = 45.9%  2.3%, ACs = 36.3%  3.2%,
and TCAs = 32.3%  4.4%. ADR dropout rates were:
ACs = 12.3%  1.8% (N = 1,259), SNRIs = 12.0%  2.3%
(N = 732), TCAs = 11.7%  2.7% (N = 267). CONCLUSION:
For all success measures, SNRIs rates were highest, then ACs, then
TCAs. Dropout rates were comparable among drug classes.
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OBJECTIVE: To use clinician reported data pre- and post-
operative in bariatric surgery patients to create an algorithm for
the development of a standardized tool, for use by bariatric
surgeons within a conﬁdence interval, to determine the
maximum weight loss threshold from roux en y surgery by the
third physician visit. METHODS: Retrospective database
analysis (2000–2007) of empirical clinical data, pre- and
post-operative, for bariatric patients in Western New York. A
multivariate model examined the relationship between % excess
body weight lost (BWL) at the ﬁrst three post-operative visits and
% BWL at the sixth post-operative visit (V6), using SAS 9.1.
Percent excess BWL was plotted vs. days elapsed from surgery.
179 obese adults (women = 155, 86.6%) received gastric bypass
surgery, mean BMI = 53, (SD = 9.6), mean excess body weight at
time of procedure = 185 lbs (SD = 65.3). RESULTS: Outcomes
were available for 158 patients (women = 137, 86.7%) at V6
(mean = 707 days), mean BMI = 35.2 (SD = 7.7), women = 34.7
vs. men = 38.1. Mean % excess BWL at V6 was 60%
(SD = 18%). Women had more BWL than men (61% vs. 55%).
For females, BWL was maximized at 870 days post-operation,
the equation ﬁt for males did not yield an absolute maximum,
leveling off at 740 days (monthly change rate < 0.5%/month).
Our model included linear and non-linear components to corre-
late the relationship between the total % excess BWL at V6 and
% excess BWL at the ﬁrst three visits. All variables, except BWL
at the second visit, were statistically signiﬁcant. The algorithm
had a predictive accuracy of 94%. CONCLUSION: The excess
BWL at the third visit is predictive of the ﬁnal excess BWL,
following surgery. Gender and initial BMI displayed signiﬁcant
relationships with ﬁnal weight loss. The algorithm derived from
this sample will support the development of a standardized tool
to assist physicians in their post-operative prognosis of gastric
bypass patients.
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OBJECTIVE: To assess the ability of BTX-A injections to lower
migraine frequency in chronic sufferers. METHODS: Two re-
viewers independently searched PubMed, Google Scholar and
Cochrane Library to locate randomized, double-blind, placebo-
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